Skip to main content

Advertisement

SpringerLink
Log in

Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Locally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis. FOLFIRINOX and gemcitabine/nab-paclitaxel have proven effective in the metastatic setting. We sought to evaluate the outcomes of these regimens compared with older regimens in LAPC.

Methods

A retrospective, single institutional review of all consecutive LAPC treated with “new” (FOLFIRINOX and/or gemcitabine/nab-paclitaxel) and “old” (gemcitabine or 5-FU) chemotherapy from 2010 to 2014 was performed. Univariate and multivariate predictors of resection and survival were determined.

Results

A total of 92 patients (new chemotherapy = 61, old chemotherapy = 31) were analyzed, of which 19 (21%) underwent eventual resection (median overall survival [OS] = 32 vs. 14.3 months for unresected patients, P = 0.0002). For the overall cohort, resection (hazard ratio [HR] 0.261, P = 0.014), radiation therapy (HR 0.458, P = 0.004), number of lines of chemotherapy (HR 0.486, P = 0.012), and new chemotherapy (HR 0.593 vs. old regimens, P = 0.065) were independent predictors of OS on multivariate analyses (MVA). On MVA, predictors of eventual resection were head and neck tumors (OR 0.307, P = 0.033) or SMA involvement (OR 0.285, P = 0.023). In nonresected patients (73), MVA showed treatment with new chemotherapy (HR 0.452, P = 0.006), radiation (HR 0.459, P = 0.006), and number of lines of CT (HR 0.705, P = 0.013) to be predictors of survival.

Conclusions

In LAPC, use of FOLFIRNOX and/or gemcitabine/nab-paclitaxel is associated with improved survival compared with older chemotherapy regimens, regardless of eventual resection. Tumor location and relationship to certain vasculature are important determinants of resection in this cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770–8. doi:10.1200/JCO.2014.59.7930.

    Article  PubMed  Google Scholar 

  2. Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12. doi:10.1200/JCO.2011.34.8904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2. Ann Oncol. 2008;19(9):1592–9. doi:10.1093/annonc/mdn281.

    Article  CAS  PubMed  Google Scholar 

  4. Hammel P, Huguet F, Van Laethem J-L, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. ASCO Meet Abstr. 2013;31(15_suppl):LBA4003. http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/LBA4003. Accessed 28 Mar 2016.

  5. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26. doi:10.1016/S1470-2045(13)70021-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326–31. doi:10.1200/JCO.2006.07.5663.

    Article  CAS  PubMed  Google Scholar 

  7. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    Article  CAS  PubMed  Google Scholar 

  8. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373–8.

    Article  CAS  PubMed  Google Scholar 

  9. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol. 1981;32(3):164–5.

    CAS  PubMed  Google Scholar 

  10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.

    Article  PubMed  Google Scholar 

  11. NCCN guidelines version2.2015.https://www.nccn.org//professionals/physician_gls/pdf/pancreatic.

  12. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi:10.1056/NEJMoa1011923.

    Article  CAS  PubMed  Google Scholar 

  13. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi:10.1056/NEJMoa1304369.

    Article  Google Scholar 

  14. Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236–41. doi:10.1002/jso.23392.

    Article  CAS  PubMed  Google Scholar 

  15. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12(1):199. doi:10.1186/1471-2407-12-199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1):361. doi:10.1007/s12032-012-0361-2.

    Article  PubMed  Google Scholar 

  17. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42(8):1311–5. doi:10.1097/MPA.0b013e31829e2006.

    Article  CAS  PubMed  Google Scholar 

  18. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18(5):543–8. doi:10.1634/theoncologist.2012-0435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Moorcraft SY, Khan K, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13(4):232–8. doi:10.1016/j.clcc.2014.09.005.

    Article  PubMed  Google Scholar 

  20. Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295–301. doi:10.1245/s10434-014-3898-9.

    Article  CAS  PubMed  Google Scholar 

  21. Sadot E, Doussot A, O’Reilly EM, et al. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512–21. doi:10.1245/s10434-015-4647-4.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9. doi:10.1245/s10434-014-4225-1.

    Article  PubMed  Google Scholar 

  23. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7. doi:10.1097/SLA.0000000000000867.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-10. doi:10.1016/S1470-2045(16)00172-8.

    Article  CAS  PubMed  Google Scholar 

  25. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-56. doi:10.1002/cncr.27636.

    Article  PubMed  Google Scholar 

  26. Boone BA, Steve J, Zenati MS, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21(13):4351–8. doi:10.1245/s10434-014-3842-z.

    Article  PubMed  Google Scholar 

  27. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794–801. doi:10.1245/s10434-010-0943-1.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, et al. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 2015;17(10):942-52. doi:10.1111/hpb.12448.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Moningi S, Dholakia AS, Raman SP, et al: The Role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol. 2015;22:2352–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654–68.

    Article  PubMed  Google Scholar 

Download references

Disclosure

None

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA

    Filip Bednar MD, PhD, Mazen S. Zenati MD, MPH, PhD, Jennifer Steve BS, Lee M. Ocuin MD, Melissa E. Hogg MD, Herbert J. Zeh III MD & Amer H. Zureikat MD

  2. UPMC Network Cancer Registry, University of Pittsburgh, Pittsburgh, PA, USA

    Sharon Winters MS

  3. Division of Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Nathan Bahary MD, PhD

Authors
  1. Filip Bednar MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mazen S. Zenati MD, MPH, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer Steve BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sharon Winters MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lee M. Ocuin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nathan Bahary MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melissa E. Hogg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Herbert J. Zeh III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amer H. Zureikat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amer H. Zureikat MD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 281 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bednar, F., Zenati, M.S., Steve, J. et al. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?. Ann Surg Oncol 24, 1406–1413 (2017). https://doi.org/10.1245/s10434-016-5707-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5707-0

Keywords

Search

Navigation